Vitiligo

Patients treated with ruxolitnib cream show ≥75% improvement in facial vitiligo scoring index.

Seemal Desai, MD, gives an overview of the most promising research and therapies for patient of color populations.

A pair of AAD VMX studies show long-term repigmentization is possible with the JAK inhibitor. An expert explains why the drug could make history.

According to a systematic review and meta-analysis of 8776 unique patients, 52.69% achieved repigmentation of >90%.

Skin pigmentation disorders do not always have a cure or treatment, and they may cause social or emotional burdens for the patient.

In the inaugural episode of Derm Discussions, Seemal Desai, MD, joins Brad Glick, DO, for an update on dermatologic burdens in people of color.

Patients afflicted with vitiligo often have significant differences in Schirmer test results, lens, and fundus findings.

Patients with vitiligo have a choice of many treatment options, which run the gamut from applying make-up to depigmented areas, to light treatment, all the way up to surgery to move pigmented skin cells to affected areas. Yet, many patients elect not to treat the condition at all, despite the fact that the condition can be emotionally devastating and progressive.